(Reuters) - Private equity firms are mulling over a $10 billion plan to buy and merge older drug brands of Britain’s GlaxoSmithKline (GSK.L) and France’s Sanofi (SASY.PA), the Financial Times reported on Sunday, citing sources.
U.S.-based KKR (KKR.N) and Warburg Pincus WP.UL were among the firms considering making bids for assets owned by GSK and Sanofi, the newspaper quoted several people familiar with the matter as saying. (on.ft.com/1oo8n5j)
GSK Chief Executive Andrew Witty in April said the drugmaker was reviewing its portfolio of mature products and wanted to dispose of off-patent drugs marketed in North America and Western Europe.
Help employers find you! Check out all the jobs and post your resume.
